Andros Pharmaceuticals Co (ROCO:6917) Other Current Payables: NT$18.69 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
40 GF Score
Price NT$30.90
GF Value NT$165.96
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Other Current Payables?

Andros Pharmaceuticals Co ROCO:6917 -0.48% 40 Other Current Payables is NT$18.69 Mil as of Dec. 2025. GuruFocus rates ROCO:6917 with a GF Score™ of 40/100 and a GF Value™ of NT$165.96 (Possible Value Trap). The stock has 4 warning signs investors should review.

Andros Pharmaceuticals Co's Other Current Payables for the quarter that ended in Dec. 2025 was NT$18.69 Mil.

Andros Pharmaceuticals Co's quarterly Other Current Payables declined from Dec. 2024 (NT$20.71 Mil) to Jun. 2025 (NT$14.56 Mil) but then increased from Jun. 2025 (NT$14.56 Mil) to Dec. 2025 (NT$18.69 Mil).

Andros Pharmaceuticals Co's annual Other Current Payables declined from Dec. 2023 (NT$26.47 Mil) to Dec. 2024 (NT$20.71 Mil) and declined from Dec. 2024 (NT$20.71 Mil) to Dec. 2025 (NT$18.69 Mil).

Andros Pharmaceuticals Co Other Current Payables Related Terms

Andros Pharmaceuticals Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Other Current Payables Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 12.62 14.31 26.47 20.71 18.69

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.47 13.02 20.71 14.56 18.69
ROCO:6917
40GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$18.69 Mil mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Other Current Payables of NT$18.69 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Andros Pharmaceuticals Co and its competitors.
Is Andros Pharmaceuticals Co's Other Current Payables too high?
Andros Pharmaceuticals Co's current Other Current Payables is NT$18.69 Mil. Overall, Andros Pharmaceuticals Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Other Current Payables compare to VRTX and REGN?
Andros Pharmaceuticals Co's Other Current Payables of NT$18.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Other Current Payables is NT$18.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.96, compared to a current price of NT$30.90 — trading 81.4% below its estimated fair value. The current Other Current Payables is NT$18.69 Mil. Andros Pharmaceuticals Co's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Other Current Payables is NT$18.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$30.90 is trading 81.4% below its estimated GF Value™ of NT$165.96. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Other Current Payables: NT$18.69 Mil
  • GF Value™: NT$165.96 vs. price of NT$30.90 (81.4% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
40GF Score

Get the complete analysis for ROCO:6917

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.90
Price
NT$165.96
GF Value